Pentalgin n composition in Latin. Piralgin. In which part of the gastrointestinal tract do Pentalgin tablets dissolve? And can they be used to relieve stomach pain?
Pentalgin-N: instructions for use and reviews
Latin name: Pentalginum-N
ATX code: N02BB72
Active substance: codeine + caffeine + metamizole sodium + naproxen + phenobarbital (codeine + caffeine + metamizole sodium + naproxen + phenobarbital)
Manufacturer: Pharmstandard-Tomskkhimpharm, JSC (Russia)
Updating the description and photo: 22.11.2018
Pentalgin-N is a combination drug with analgesic, antipyretic and anti-inflammatory effects.
Release form and composition
Dosage form of Pentalgin-N - tablets: flat-cylindrical in shape, from white to white with a creamy or yellowish tint, with the abbreviated name of the drug "PENT-N" printed on one side (in cell or cell-free contour packaging of 10 pcs., in cardboard box 1 or 2 packs).
Composition of one tablet:
- active substances: analgin (metamizole sodium) – 300 mg, naproxen – 100 mg, caffeine – 50 mg, phenobarbital – 10 mg, codeine (in the form of codeine or codeine phosphate) – 8 mg;
- auxiliary components: potato starch, low molecular weight povidone (medical low molecular weight polyvinylpyrrolidone), sodium citrate, magnesium stearate.
Pharmacological properties
Pharmacodynamics
IN composition of Pentalgina-N includes active substances that have analgesic, antispasmodic, antipyretic, anti-inflammatory and sedative effects.
Metamizole sodium is a pyrazolone derivative. It has analgesic and antipyretic effects.
Naproxen, being a non-steroidal anti-inflammatory drug, has anti-inflammatory, analgesic and antipyretic properties, which are caused by non-selective inhibition of the activity of the cyclooxygenase enzyme, which is responsible for the production of prostaglandins from arachidonic acid.
Caffeine promotes expansion blood vessels skeletal muscle tissue, heart, brain, kidneys, increasing physical and mental performance, reducing fatigue and drowsiness. By increasing the permeability of histohematic barriers and increasing the bioavailability of non-narcotic analgesics, caffeine leads to an increase in their therapeutic effect.
Codeine has the property of stimulating opioid receptors in various departments central nervous system, leading to activation of the antinociceptive system and improved perception of pain at the emotional level.
Phenobarbital and codeine increase the analgesic effect of metamizole sodium and naproxen.
Pharmacokinetics
The active substances of the drug are well absorbed in the gastrointestinal tract.
Some pharmacokinetic characteristics active ingredients Pentalgina-N:
- metamizole sodium: hydrolyzes in the intestinal wall, forming the active metabolite 4-methyl-amino-antipyrine, which is metabolized, in turn, into 4-formyl-amino-antipyrine and other metabolites. 50–60% of the active metabolite is bound to plasma proteins. The substance is capable of penetrating into breast milk. Metabolites are excreted in the urine;
- naproxen: bioavailability is 95%, binds to plasma proteins. The half-life (T1/2) ranges from 12 to 15 hours. Excreted primarily by the kidneys in the form of a metabolite (dimethylnaproxen), with bile - in small quantities;
- caffeine: well absorbed in the intestines. T1/2 is 5 hours (in some cases – up to 10 hours). Excreted mainly in the urine in the form of metabolites, unchanged - approximately 10%;
- phenobarbital: bioavailability - about 80%, approximately 50% binds to plasma proteins. Has the ability to penetrate well through the placental barrier. Metabolism occurs in the liver with the formation of metabolites, the main of which does not have pharmacological activity. Excreted in urine, including unchanged form, – 20–25%;
- codeine: slightly bound to plasma proteins. Metabolized in the liver. By demethylation, 10% of the substance is converted to morphine. It is excreted mainly by the kidneys, unchanged – 5–15%.
Indications for use
- pain syndrome of various origins mild to moderate severity (including headache, neuralgia, migraine, pain in muscles, joints, radiculitis, toothache, algodismenorrhea);
- colds and other diseases accompanied by fever, inflammation and pain.
Contraindications
Absolute:
- severe renal and/or liver dysfunction;
- anemia, leukopenia;
- bronchial asthma, bronchospasm;
- respiratory depression;
- stomach ulcer and/or duodenum in the acute stage;
- severe arterial hypertension;
- acute myocardial infarction;
- arrhythmias;
- traumatic brain injuries;
- glaucoma;
- deficiency of glucose-6-phosphate dehydrogenase;
- state of alcoholic intoxication;
- childhood up to 12 years;
- pregnancy, lactation period;
- increased individual sensitivity to any component included in Pentalgin-N.
Relative (use of the drug requires caution):
- mild arterial hypertension and medium degree heaviness;
- peptic ulcer of the stomach and/or duodenum in remission;
- elderly age.
Instructions for use of Pentalgin-N: method and dosage
Pentalgin-N tablets are taken orally.
Side effects
- from the central nervous system: dizziness, drowsiness;
- from the outside digestive system: nausea, vomiting, epigastric pain, constipation; with prolonged use of high doses – liver dysfunction;
- from the outside of cardio-vascular system: heartbeat;
- from the hematopoietic system: rarely - hematopoietic disorders (granulocytopenia, leukopenia, agranulocytosis);
- from the urinary system: with prolonged use in high doses– renal dysfunction;
- allergic reactions: itching, skin rash, urticaria.
Overdose
In case of an overdose of Pentalgin-N, the development of the following symptoms: nausea, vomiting, drowsiness, weakness, gastralgia, disorders heart rate, tachycardia, delirium, respiratory depression.
Treatment in case of overdose consists of inducing vomiting, gastric lavage through a tube, and the use of adsorbents (for example, activated carbon), symptomatic therapy aimed at maintaining the functioning of vital organs.
special instructions
While taking Pentalgin-N, it may be difficult to make a diagnosis in the case of acute abdominal pain syndrome.
In patients with hay fever and atopic bronchial asthma the use of the drug increases the risk of developing reactions hypersensitivity.
In the case of long-term (more than five days) use of Pentalgin-N, it is necessary to monitor liver function indicators and peripheral blood patterns.
During the period of use of the drug, the results of doping control in athletes may change.
Impact on the ability to drive vehicles and complex mechanisms
Since Pentalgin-N can cause such adverse reactions as dizziness and drowsiness, you should refrain from driving while taking pills Vehicle and performing potentially hazardous activities that require increased concentration and rapid psychomotor reactions.
Use during pregnancy and lactation
According to the instructions, Pentalgin-N is contraindicated for use by pregnant and breastfeeding women.
If necessary, use the drug during the lactation period breast-feeding should be stopped.
Use in childhood
Pentalgin-N is prohibited for children under 12 years of age.
For impaired renal function
Take the drug to patients with severe renal failure contraindicated.
For liver dysfunction
In case of severe liver dysfunction, it is not recommended to prescribe Pentalgin-N.
Use in old age
Elderly patients should be careful when taking the drug.
Drug interactions
The use of Pentalgin-N simultaneously with certain medicines may lead to the development of the following effects:
Keep away from children.
Shelf life – 3 years.
The last update of the description by the manufacturer was 07/01/2002
Filterable list
Active substance:
ATX
Pharmacological groups
Nosological classification (ICD-10)
Composition and release form
1 tablet contains metamizole sodium 0.3 g, naproxen 0.1 g, caffeine 0.05 g, codeine (base) 0.008 g and phenobarbital 0.01 g; 10 pcs in a blister pack, 1 or 2 packs in a box.
pharmachologic effect
pharmachologic effect- sedative, antispasmodic, anti-inflammatory, antipyretic, analgesic.Has properties sedatives(phenobarbital), non-narcotic analgesics and NSAIDs (metamizole, naproxen), enhanced by codeine (blocks opiate receptors) and caffeine (increases the permeability of histohematic barriers).
Indications of the drug Pentalgin-N ®
Moderately severe pain syndrome: toothache and headache, myalgia, arthralgia, radiculitis, neuralgia, algodismenorrhea, etc.; feverish conditions, colds and other diseases accompanied by pain and inflammation.
Contraindications
Hypersensitivity, peptic ulcer of the stomach and duodenum (in the acute stage), blood diseases, conditions accompanied by respiratory depression, increased intracranial pressure, traumatic brain injury, acute myocardial infarction, heart rhythm disturbances, hypertension, alcohol intoxication, acute attack bronchial asthma, glaucoma, severe impairment of liver and/or kidney function, pregnancy, breastfeeding, children under 12 years of age.
Use during pregnancy and breastfeeding
Contraindicated during pregnancy. Breastfeeding should be stopped during treatment.
Side effects
From the nervous system and sensory organs: dizziness, drowsiness.
From the cardiovascular system and blood (hematopoiesis, hemostasis): granulocyto- or leukopenia, agranulocytosis.
From the gastrointestinal tract: nausea, vomiting, constipation, erosive and ulcerative lesions of the gastrointestinal tract.
Allergic reactions: skin rash, itching, urticaria.
Other: impaired renal function (with long-term use).
Interaction
Strengthens toxic effect non-opioid analgesics, reduces the plasma concentration of cyclosporine. Tricyclic antidepressants, oral contraceptives, allopurinol enhance the toxic effect of metamizole sodium; barbiturates, phenylbutazone - weaken. Sedatives and tranquilizers enhance the analgesic effect of Pentalgin-N.
Directions for use and doses
Inside, 1 tablet 1-3 times a day. Maximum daily dose— 4 tables. The course of treatment is no more than 5 days.
Overdose
Symptoms: nausea, vomiting, stomach pain, tachycardia, arrhythmia, respiratory depression.
Treatment: gastric lavage, administration of adsorbents; symptomatic therapy.
Precautionary measures
Caution should be used in cases of impaired liver and kidney function, peptic ulcer stomach and duodenum (in remission), elderly patients. With long-term use, it is necessary to monitor the composition of peripheral blood. During therapy, alcohol should be avoided and administered with caution to vehicle drivers and people whose profession involves increased concentration of attention during work.
Storage conditions for the drug Pentalgin-N ®
In a dry place, protected from light, at a temperature not exceeding 25 °C.Keep out of the reach of children.
Shelf life of the drug Pentalgin-N ®
3 years.Do not use after the expiration date stated on the package.
Synonyms of nosological groups
| Category ICD-10 | Synonyms of diseases according to ICD-10 |
|---|---|
| G43 Migraine | Migraine pain |
| Hemicrania | |
| Hemiplegic migraine | |
| Migraine headache | |
| Migraine | |
| Migraine attack | |
| Serial headache | |
| K08.8.0* Toothache | Anesthesia in dentistry |
| Pain syndromes in dental practice | |
| Dentin pain | |
| Pulp pain | |
| Pain after tartar removal | |
| Pain after dental procedures | |
| Pain during tooth extraction | |
| Dentin pain | |
| Toothache | |
| M25.5 Joint pain | Arthralgia |
| Pain syndrome in muscular and joint diseases | |
| Pain syndrome in osteoarthritis | |
| Pain syndrome in osteoarthritis | |
| Pain syndrome in acute inflammatory diseases musculoskeletal system | |
| Pain syndrome in chronic inflammatory diseases of the musculoskeletal system | |
| Pain in the joints | |
| Joint pain | |
| Joint pain during heavy physical activity | |
| Painful inflammatory joint lesions | |
| Painful conditions of the musculoskeletal system | |
| Painful joint conditions | |
| Painful traumatic lesions joints | |
| Pain in the musculoskeletal system | |
| Shoulder pain | |
| Joint pain | |
| Joint pain | |
| Joint pain due to injury | |
| Musculoskeletal pain | |
| Osteoarthritis pain | |
| Pain due to joint pathology | |
| Rheumatoid arthritis pain | |
| Pain in chronic degenerative bone diseases | |
| Pain in chronic degenerative joint diseases | |
| Osteoarticular pain | |
| Rheumatic pain | |
| Rheumatic pains | |
| Joint pain | |
| Joint pain of rheumatic origin | |
| Joint pain syndrome | |
| Joint pain | |
| M79.2 Neuralgia and neuritis, unspecified | |
| Brachialgia | |
| Occipital and intercostal neuralgia | |
| Neuralgia | |
| Neuralgic pain | |
| Neuralgia | |
| Neuralgia of the intercostal nerves | |
| Neuralgia of the posterior tibial nerve | |
| Neuritis | |
| Traumatic neuritis | |
| Neuritis | |
| Neurological pain syndromes | |
| Neurological contractures with spasms | |
| Acute neuritis | |
| Peripheral neuritis | |
| Post-traumatic neuralgia | |
| Severe neurogenic pain | |
| Chronic neuritis | |
| Essential neuralgia | |
| R50 Fever of unknown origin | Hyperthermia malignant |
| Malignant hyperthermia | |
| R51 Headache | Head pain |
| Pain due to sinusitis | |
| Pain in the back of the head | |
| Headache | |
| Headache of vasomotor origin | |
| Headache of vasomotor origin | |
| Headache with vasomotor disturbances | |
| Headache | |
| Neurological headache | |
| Serial headache | |
| Cephalgia | |
| R52.2 Other persistent pain | Pain syndrome of non-rheumatic origin |
| Pain syndrome with vertebrogenic lesions | |
| Pain syndrome with neuralgia | |
| Pain syndrome from burns | |
| Pain syndrome is mild or moderate | |
| Neuropathic pain | |
| Neuropathic pain | |
| Perioperative pain | |
| Moderate to severe pain | |
| Moderate or mild pain syndrome | |
| Moderate to severe pain syndrome | |
| Ear pain due to otitis media |
The combined drug has analgesic, antipyretic and anti-inflammatory effects.
Metamizole sodium is an analgesic-antipyretic, a pyrazolone derivative. Has a pronounced analgesic effect.
Naproxen is an NSAID that has anti-inflammatory, analgesic and antipyretic effects associated with non-selective suppression of COX activity, which regulates the synthesis of prostaglandins.
Caffeine causes dilation of blood vessels in skeletal muscles, brain, heart, and kidneys. Increases mental and physical performance, helps eliminate fatigue and drowsiness. Increases the permeability of histohematic barriers and increases the bioavailability of non-opioid analgesics, thereby enhancing the therapeutic effect.
Codeine stimulates opioid receptors in various parts of the central nervous system, which leads to activation of the antinociceptive system and a change in the emotional perception of pain.
Phenobarbital and codeine increase the analgesic effect of metamizole sodium and naproxen.
Pharmacokinetics
The components of the drug are well absorbed from the gastrointestinal tract.
Metamizole sodium
In the intestinal wall it is hydrolyzed to form the active metabolite, 4-methyl-amino-antipyrine, which in turn is metabolized to 4-formyl-amino-antipyrine and other metabolites. The binding of the active metabolite to proteins is 50-60%. Metabolites are excreted by the kidneys and excreted in breast milk.
Naproxen
Bioavailability is 95%. Binds to blood proteins. T1/2 - 12-15 hours. Excreted in the urine mainly in the form of a metabolite (dimethylnaproxen), in small quantities - in bile.
Well absorbed in the intestines. T 1/2 - 5 hours (sometimes up to 10 hours). It is excreted mainly by the kidneys in the form of metabolites, about 10% - unchanged.
Slightly binds to plasma proteins. It undergoes biotransformation in the liver (10% goes into morphine by demethylation). Excreted by the kidneys (5-15% unchanged).
Phenobarbital
Bioavailability is 80%. Binding to blood plasma proteins - 50%. Penetrates well through the placental barrier. Biotransformed in the liver. The main metabolite has no pharmacological activity. Excreted by the kidneys, incl. 20-25% - unchanged.
Release form
Tablets are white or white with a yellowish or creamy tint, flat-cylindrical, with the abbreviated name of the drug "PENT-N" embossed on one side.
Excipients: potato starch, low molecular weight polyvinylpyrrolidone (povidone), sodium citrate, magnesium stearate.
10 pieces. - contour cellular packaging (1) - cardboard packs.
Dosage
The drug is prescribed 1 tablet. 1-3 times/day. The maximum daily dose is 4 tablets.
The drug should not be taken for more than 5 days as an analgesic and for more than 3 days as an antipyretic without a doctor’s prescription.
Overdose
Symptoms: nausea, vomiting, gastralgia, drowsiness, tachycardia, cardiac arrhythmias, delirium, weakness, respiratory depression.
Treatment: induction of vomiting, gastric lavage through a tube, administration of adsorbents (activated carbon), symptomatic therapy aimed at maintaining vital functions.
Interaction
Concomitant use of the drug with other non-opioid analgesics may lead to increased toxic effects.
Tricyclic antidepressants, oral contraceptives, and allopurinol increase the toxicity of metamizole sodium, which is part of the drug.
Barbiturates, phenylbutazone and other inducers of microsomal liver enzymes weaken the effect of metamizole sodium.
The simultaneous use of metamizole sodium with cyclosporine reduces the level of the latter in the blood.
Sedatives and tranquilizers enhance the analgesic effect of the drug.
Side effects
From the digestive system: epigastric pain, nausea, vomiting, constipation; with long-term use in high doses - liver dysfunction.
From the hematopoietic system: rarely - inhibition of hematopoiesis (leukopenia, granulocytopenia, agranulocytosis).
From the side of the central nervous system: dizziness, drowsiness.
From the cardiovascular system: palpitations.
From the urinary system: with long-term use in high doses - impaired renal function.
Allergic reactions: skin rash, itching, urticaria.
Indications
- mild and moderate pain syndrome of various origins (including pain in joints, muscles, radiculitis, algodismenorrhea, neuralgia, headache, migraine, toothache);
- fevers, colds and other diseases accompanied by pain and inflammation.
Contraindications
- severe liver failure;
- severe renal failure;
- peptic ulcer of the stomach and duodenum in the acute phase;
- bronchial asthma;
- bronchospasm;
- anemia, leukopenia;
- conditions accompanied by respiratory depression;
- traumatic brain injury;
- severe arterial hypertension;
- acute myocardial infarction;
- arrhythmias;
- alcohol intoxication;
- glaucoma;
- deficiency of glucose-6-phosphate dehydrogenase;
- pregnancy;
- children under 12 years of age;
- hypersensitivity to the components of the drug.
The drug should be used with caution in mild to moderate arterial hypertension, gastric and/or duodenal ulcers in remission, as well as in elderly patients.
Features of application
Use during pregnancy and breastfeeding
The drug is contraindicated for use during pregnancy and lactation (breastfeeding).
If it is necessary to prescribe the drug during lactation, breastfeeding should be stopped.
Use for liver dysfunction
The drug is contraindicated for use in cases of severe liver dysfunction.Use for renal impairment
The drug is contraindicated for use in cases of severe renal impairment.Use in children
Contraindication: children under 12 years of age.Use in elderly patients
The drug should be used with caution in elderly patients.special instructions
With long-term (more than 5 days) use of the drug, it is necessary to monitor the peripheral blood picture and liver function indicators.
Taking the drug Pentalgin ® -N may complicate the diagnosis of acute abdominal pain syndrome.
Patients with atopic bronchial asthma and hay fever have an increased risk of developing hypersensitivity reactions while taking the drug Pentalgin ® -N.
The use of the drug may change the results of doping control in athletes.
Impact on the ability to drive vehicles and operate machinery
When taking the drug Pentalgin ® -N, you should refrain from driving vehicles and potentially dangerous species activities that require increased concentration and speed of psychomotor reactions.
According to the Decree of the Government of the Russian Federation dated July 20, 2011 No. 599 (as amended on December 22, 2011) “On control measures regarding drugs that contain small quantities narcotic drugs, psychotropic substances and their precursors included in the list of narcotic drugs, psychotropic substances and their precursors subject to control in Russian Federation»
establish a standard for prescription dispensing of combination drugs intended for medical use, containing small amounts of codeine or its salts, which comes into force on June 1, 2012.
From June 1, 2012, all combination drugs containing codeine or its salts in amounts up to 20 mg per 1 solid dose dosage form or up to 200 mg per 100 ml/100 mg liquid dosage form for internal use, are subject to release from pharmacies and pharmacy points according to prescriptions.
I. For dispensing medications
Use the prescription form: No. 107-1/у “Prescription form” (validity of the prescription is 2 months or 1 year) and No. 148-1/у-88 “Prescription form” (validity of the prescription is 10 days or 1 month).
Norm for dispensing medications: according to the prescription form form No. 107-1/u “Prescription form” = no more than 3 medications without any corrections, and according to the prescription form form No. 148-1/u-88 “Prescription form” = only one drug without any correction.
The following combination medications containing:
a) codeine or its salts in an amount of up to 20 mg (per 1 dose of solid dosage form), or up to 200 mg (per 100 ml or 100 g of liquid dosage form);
b) ergotamine hydrotartrate in an amount of up to 5 mg (per 1 dose of solid dosage form);
c) dextromethorphan hydrobromide in an amount exceeding 10 mg and up to 30 mg (per 1 dose of solid dosage form).
Prescriptions for combination medications written on prescription forms form No. 107-1/u (with the exception of prescriptions valid for up to 1 year in accordance with paragraph 1.17 of the Instructions) must be redeemed with the stamp of the pharmacy organization “Medicine dispensed” and returned to the patient’s hands.
To re-dispense these medications, inform the patient about the need to contact a doctor (paramedic) for a new prescription.
When dispensing combined medications according to prescriptions from a doctor (paramedic), written out on prescription forms form No. 107-1/u, and valid for 1 year, the prescription is returned to the patient indicating on the back the name or number of the pharmacy organization, signature of the pharmacy employee, quantity dispensed drug and date of release.
The next time a patient contacts a pharmacy, the notes on the previous receipt are taken into account. medicinal product. Upon expiration of the validity period, the prescription is canceled with the stamp “Prescription is invalid” and left at the pharmacy.
ATTENTION: In connection with the clarifications issued by the Ministry of Health, codeine-containing drugs are dispensed only using prescription form 148-1/u-88.
II. The following drugs should be dispensed strictly according to a prescription issued in accordance with all the requirements of the orders of the Ministry of Health, including the VALIDITY DURATION OF THE PRESCRIPTION.
Ensure that these drugs are stored according to List B:
Glycodin syrup 100 ml
Grippex No. 10, No. 20, No. 100 tab.
Gripend No. 12, No. 24 tab., No. 6, No. 60 pack.
Caffetin No. 10, No. 12 table.
Caffetin cold No. 10 table.
Codelac No. 10 tablet.
Codelac syrup 100 ml
Codterpin No. 10 tab.
No-shpalgin TBL No. 12
Nurofen plus No. 12 tablet.
Pentalgin ICN No. 12 tab.
Pentalgin N No. 10 tablet.
Pentalgin plus No. 12 tablet.
Piralgin No. 10 tablet.
Sedal-M No. 10, No. 20 tab.
Sedalgin-Neo No. 10 tab.
Solpadeine No. 12 caps.
Solpadeine No. 12 tablet. plastic box
Solpadeine No. 12 tablet. soluble
Solpadeine No. 8 tablet.
Terpin code No. 10 table.
Tetralgin No. 10 tablet.
Toff plus No. 10 caps.
Tussin Plus syrup 118 ml
Unispaz No. 12 tab.
Pentalgin N contains active ingredients: analgin, naproxen, phenobarbital, caffeine And codeine.
Additional ingredients: potato starch, magnesium stearate, povidone, sodium citrate .
Release form
Pentalgin N is produced in the form of tablets, 10 pieces in a cell package, 1-2 cells in a box.
pharmachologic effect
Pentalgin N tablets are characterized by sedative, antispasmodic, analgesic, antipyretic And anti-inflammatory Effect.
Pharmacodynamics and pharmacokinetics
This combination drug exhibits
no analgesic, antipyretic And anti-inflammatory action that is caused by its constituent components.
Naproxen is known to have an analgesic and anti-inflammatory effect. Codeine is characterized by an effect that stimulates opiate receptors in the nervous system. As a result, the antinoceceptive system is activated and the emotional sensation of pain changes. Also, codeine, together with phenobarbital, increases the analgesic effect of the other components.
Caffeine has a dilating effect on blood vessels in skeletal muscles, brain, heart and kidneys. Thanks to this, mental and physical performance increases, fatigue decreases. In addition, the permeability of histohematic barriers and the bioavailability of non-narcotic drugs increases, enhancing the therapeutic effect of the drug.
All components of the drug undergo excellent absorption in the gastrointestinal tract. As a result, several active ones are formed. The protein binding rate is about 60%. Substances are mainly excreted from the body in metabolites and a small part, approximately 10%, in unchanged form.
Indications for use
The main indications for the use of Pentalgin N are mild to moderate pain of different origins, For example:
- joint, muscle and radiculitis pain;
- pain during menstruation, ;
- , And toothache .
Also, tablets are often prescribed for treatment febrile conditions, colds and other diseases that may be accompanied pain syndromes and inflammation.
Contraindications
- hypersensitivity;
- severe forms of hepatic or;
- exacerbation of gastric and duodenal ulcers;
- , ;
- , bronchospasm , other breathing disorders;
- under 12 years of age;
- deficiency of glucose-6-phosphate dehydrogenase;
- anemia, leukopenia;
- traumatic brain injuries;
- alcohol intoxication;
- cardiovascular diseases and so on.
Side effects
During the period of treatment with Pentalgin N, negative effects may occur, often manifested by dyspeptic disorders - vomiting, nausea and skin problems in the form of rash , And . It is possible that pain may occur in epigastrium , drowsiness And heartbeat . In rare cases, inhibition of hematopoiesis develops, for example: leukopenia, or granulocytopenia.
Instructions for use Pentalgin N (Method and dosage)
The instructions for use recommend taking one tablet 1-3 times a day. In this case, the maximum permissible daily dosage is 4 tablets. This medicine can be taken as a pain reliever for up to 5 days, antipyretic – no more than 3 days. In other cases, specialist advice is required.
Overdose
Use of the drug in increased dosages for a long time can cause: nausea, vomiting, stomach pain, , weakness, drowsiness , breathing problems, delirium.
In this case, treatment is carried out involving the induction of vomiting, gastric lavage using a tube, taking adsorbents and other symptomatic therapy that helps maintain important functions.
Interaction
When combining the drug with various non-narcotic analgesics Possible increased toxic effects. Combinations with tricyclic antidepressants, contraceptives and can increase the toxicity of metamizole sodium, which is part of Pentalgin N. Simultaneous use With barbiturates, phenylbutazone and various hepatic microsomal inducers can weaken the effect of metamizole sodium. When combining metamizole sodium and lowers his level first in . Tranquilizers and various sedatives can enhance the analgesic effect of the drug.